Gene-editing firm Intellia announces IPO, deal with Regeneron
April 11, 2016 at 19:14 PM EDT
Intellia Therapeutics Inc., a biotechnology company working on “editing” defective genes, has disclosed its plans for an initial public offering.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.